SSII - NASDAQ
SS Innovations International, Inc.
$4.26
+6.2%SS Innovations International, Inc. develops surgical robotic systems. It also develops SSI Mantra, a surgical robotic system; SSI Mudra, a range of surgical instruments that supports in surgical procedures, including robotic cardiac surgery; SSI Maya, a robotic surgery platform; and OMNI 3D HD provides live 3D HD view of the surgical field in robotic surgery operating room. The company is based in Fort Lauderdale, Florida.
At a Glance
Live Snapshotssii
Cash at Beginning of Period
Last Annual Value
6.62M
3-Year CAGR
154%
5-Year CAGR
197%
10-Year CAGR
203%
SS Innovations International, Inc. Competitors Analysis of Cash at Beginning of Period
| Company | Cash at Beginning of Period | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
SS Innovations International, Inc. NASDAQ:SSII | 6.62M | 188.9% | 110.4% | 203.5% | |
 Progyny, Inc. NASDAQ:PGNY | 162.31M | 10.6% | 18.2% | N/A | |
 UFP Technologies, Inc. NASDAQ:UFPT | 13.45M | 44.6% | -11.1% | -7.6% | |
 CONMED Corporation NYSE:CNMD | 24.46M | -5.5% | -2.2% | -10.3% | |
 Omada Health NASDAQ:OMDA | 76.39M | -23.1% | N/A | N/A | |
 AdaptHealth Corp. NASDAQ:AHCO | 109.75M | 33.4% | 1.9% | 39.2% | |
 Schrödinger, Inc. NASDAQ:SDGR | 162.66M | 19.3% | -4.3% | N/A | |
 Omnicell, Inc. NASDAQ:OMCL | 398.61M | 4.2% | -4.0% | 17.1% | |
 Teladoc Health, Inc. NYSE:TDOC | 1.30B | 12.2% | 12.1% | 37.2% | |
 PROCEPT BioRobotics Corporation NASDAQ:PRCT | 336.76M | 14.3% | 27.3% | N/A |
SS Innovations International, Inc. Fair Value Envelope
Related Guides
Continue your SSII research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.